keyword
MENU ▼
Read by QxMD icon Read
search

PSA post nadir

keyword
https://www.readbyqxmd.com/read/28864223/risk-factors-for-disease-progression-after-postprostatectomy-salvage-radiation-long-term-results-of-a-single-institution-experience
#1
Danielle Rodin, Michael Drumm, Rebecca Clayman, Daniela L Buscariollo, Sigolene Galland-Girodet, Alec Eidelman, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Andrzej Niemierko, William U Shipley, Anthony L Zietman, Jason A Efstathiou
BACKGROUND: Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing. PATIENTS AND METHODS: We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013...
August 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28856702/avoidance-of-androgen-deprivation-therapy-in-radiorecurrent-prostate-cancer-as-a-clinically-meaningful-endpoint-for-salvage-cryoablation
#2
Kevin B Ginsburg, Ahmed Elshafei, Changhong Yu, J Stephen Jones, Michael L Cher
BACKGROUND: To investigate the ability of salvage cryoablation of the prostate (SCAP) to delay the need for androgen deprivation therapy (ADT) in local recurrence after radiation therapy to the prostate using the Cryo-On-Line Database (COLD) registry. METHODS: The COLD registry is comprised of a combination of retrospectively and prospectively collected data on patients undergoing primary and SCAP. Patients with local recurrence after radiation therapy were identified...
August 29, 2017: Prostate
https://www.readbyqxmd.com/read/28816074/prostate-specific-antigen-after-salvage-radiotherapy-for-postprostatectomy-biochemical-recurrence-predicts-long-term-outcome-including-overall-survival
#3
Detlef Bartkowiak, Reinhard Thamm, Dirk Bottke, Alessandra Siegmann, Dirk Böhmer, Volker Budach, Thomas Wiegel
BACKGROUND: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% of the patients experience further progression. With a focus on the pre- and post-SRT serum level of the prostate-specific antigen (PSA), we assessed the determinants of the long-term outcome after SRT. PATIENT AND METHODS: Between 1997 and 2011, 464 patients received 3D-conformal SRT with median 66...
August 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28806948/assessment-of-lower-urinary-symptom-flare-with-overactive-bladder-symptom-score-and-international-prostate-symptom-score-in-patients-treated-with-iodine-125-implant-brachytherapy-long-term-follow-up-experience-at-a-single-institute
#4
Makito Miyake, Nobumichi Tanaka, Isao Asakawa, Shunta Hori, Yosuke Morizawa, Yoshihiro Tatsumi, Yasushi Nakai, Takeshi Inoue, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Masatoshi Hasegawa, Tomomi Fujii, Noboru Konishi, Kiyohide Fujimoto
BACKGROUND: The aim of this study was to evaluate the combined use of the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) as an assessment tool for urinary symptom flare after iodine-125 ((125)I) implant brachytherapy. The association between urinary symptom flare and prostate-specific antigen (PSA) bounce was investigated. METHODS: Changes in the IPSS and OABSS were prospectively recorded in 355 patients who underwent seed implantation...
August 14, 2017: BMC Urology
https://www.readbyqxmd.com/read/28735016/timing-of-prostate-specific-antigen-nadir-after-radical-prostatectomy-and-risk-of-biochemical-recurrence
#5
Stephanie L Skove, Lauren E Howard, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Matthew R Cooperberg, Daniel M Moreira, Stephen J Freedland
OBJECTIVE: To evaluate the association between the prostate-specific antigen (PSA) nadir level and the time to nadir (TTN) with biochemical recurrence (BCR) risk after radical prostatectomy (RP) in the Shared Equal-Access Research Cancer Hospital (SEARCH) database. MATERIALS AND METHODS: This is a retrospective analysis of 1939 men from the SEARCH database treated with RP between 1998 and 2015 with available ultrasensitive PSA nadir within 1-6 months after RP. Uni- and multivariable analyses of PSA nadir and TTN with time from nadir to BCR were performed with Cox models (adjusted for demographics, tumor features, and preoperative PSA)...
July 19, 2017: Urology
https://www.readbyqxmd.com/read/28735014/initial-clinical-experience-with-testosterone-undecanoate-therapy-aveed-%C3%A2-in-testosterone-deficient-men-in-the-united-states
#6
Abraham Morgentaler, Yonah Krakowsky, William Conners, Emily Davidson, Alex Rawji
OBJECTIVE: To report our initial experiences with TU 750mg in testosterone-deficient men. METHODS: All patients receiving TU 750mg at our center between July 1 2014 to August 1 2016 were identified. Clinical response was assessed via structured interviews and laboratory evaluations. Adverse events were documented, including increases in prostate specific antigen (PSA), hematocrit (Hct), and the development of post-injection cough. RESULTS: More than two injections were received by 147 men, with mean age 63...
July 19, 2017: Urology
https://www.readbyqxmd.com/read/28670842/long-term-oncological-outcomes-and-toxicity-in-597-men-aged-%C3%A2-60%C3%A2-years-at-time-of-low-dose-rate-brachytherapy-for-localised-prostate-cancer
#7
Stephen E M Langley, Ricardo Soares, Jennifer Uribe, Santiago Uribe-Lewis, Julian Money-Kyrle, Carla Perna, Sara Khaksar, Robert Laing
OBJECTIVES: To report oncological and functional outcomes of men treated with low-dose-rate (LDR) prostate brachytherapy aged ≤60 years at time of treatment. PATIENTS AND METHODS: Of 3262 patients treated with LDR brachytherapy at our centre up to June 2016, we retrospectively identified 597 patients aged ≤60 years at treatment with ≥3-years post-implantation follow-up and four prostate-specific antigen (PSA) measurements, of which one was at baseline. Overall survival (OS), prostate cancer-specific survival (PCSS) and relapse free survival (RFS) were analysed together with prospectively collected physician-reported adverse events and patient-reported symptom scores...
July 3, 2017: BJU International
https://www.readbyqxmd.com/read/28652121/high-intensity-focused-ultrasound-for-radio-recurrent-prostate-cancer-a-north-american-clinical-trial
#8
Tonye A Jones, Joseph Chin, David Mcleod, Jack Barkin, Allan Pantuck, Leonard S Marks
PURPOSE: To determine the safety and efficacy of whole-gland HIFU in men with radio-recurrent prostate cancer (CaP). MATERIALS AND METHODS: 100 men with clinically localized recurrence of CaP at least 2 years after EBRT received whole-gland HIFU in an open-label trial (2009 to 2012). Treatments were performed at 16 sites in the U.S. (14) and Canada (2). Primary endpoint was a combination of both PSA nadir ≤0.5 ng/ml and negative biopsy at 12 months. Validated questionnaires were used to monitor changes in urinary and sexual function...
June 23, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28548372/initial-multicentre-experience-of-68-gallium-psma-pet-ct-guided-robot-assisted-salvage-lymphadenectomy-acceptable-safety-profile-but-oncological-benefit-appears-limited
#9
Amila Siriwardana, James Thompson, Pim J van Leeuwen, Shaela Doig, Anton Kalsbeek, Louise Emmett, Warick Delprado, David Wong, Hemamali Samaratunga, Anne-Maree Haynes, Geoff Coughlin, Phillip Stricker
OBJECTIVES: To evaluate the safety and short-term oncological outcomes for (68) Ga-PSMA PET/CT directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for (68) Ga-PSMA PET/CT detected oligometastatic nodal recurrence. RASND was performed by targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease...
May 26, 2017: BJU International
https://www.readbyqxmd.com/read/28437170/prostate-specific-antigen-nadir-of-0-1-or-less-is-a-predictor-of-treatment-success-in-men-undergoing-salvage-whole-prostate-gland-cryoablation
#10
Yaw A Nyame, Ahmed Elshafei, Daniel J Greene, Hans C Arora, Robert W Given, Kae Jack Tay, Thomas J Polascik, Ashley E Ross, Vladimir B Mouraviev, Franco Lugnani, J Stephen Jones
PURPOSE: To assess factors that affect prostate biopsy results following salvage whole gland cryoablation. PATIENTS AND METHODS: One hundred seventy-four patients underwent prostate biopsy following salvage whole gland cryoablation of the prostate in the Cryo-OnLine Database registry. Wilcoxon rank-sum and χ(2) tests and logistic regression analysis were used to assess predictors of positive biopsy. Prostate specific antigen (PSA) nadir was divided into a statistical tertile for comparisons between different nadir PSA cut points...
May 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28410986/predictors-of-biochemical-recurrence-after-primary-focal-cryosurgery-hemiablation-for-localized-prostate-cancer-a-multi-institutional-analytic-comparison-of-phoenix-and-stuttgart-criteria
#11
Michael Kongnyuy, Michael J Lipsky, Shahidul Islam, Dennis J Robins, Shaun Hager, Daniel M Halpern, Kaitlin E Kosinski, Jeffrey T Schiff, Anthony T Corcoran, Sven Wenske, Aaron E Katz
BACKGROUND: The Phoenix definition (PD) and Stuttgart definition (SD) designed to determine biochemical recurrence (BCR) in patients with postradiotherapy and high-intensity focused ultrasound organ-confined prostate cancer are being applied to follow patients after cryosurgery. We sought to identify predictors of BCR using the PD and SD criteria in patients who underwent primary focal cryosurgery (PFC). MATERIALS AND METHODS: We performed a retrospective review of patients who underwent PFC (hemiablation) at 2 referral centers from 2000 to 2014...
April 11, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28323339/adjuvant-radiation-therapy-androgen-deprivation-and-docetaxel-for-high-risk-prostate-cancer-postprostatectomy-results-of-nrg-oncology-rtog-study-0621
#12
Mark D Hurwitz, Jonathan Harris, Oliver Sartor, Ying Xiao, Bobby Shayegan, Paul W Sperduto, Kasra R Badiozamani, Colleen A F Lawton, Eric M Horwitz, Jeff M Michalski, Kevin Roof, David C Beyer, Qiang Zhang, Howard M Sandler
BACKGROUND: Phase 3 trials have demonstrated a benefit from adjuvant radiation therapy (ART) for men who have adverse factors at radical prostatectomy (RP). However, some patients have a high risk of progression despite ART. The role of systemic therapy with ART in this high-risk group remains to be defined. METHODS: Patients who had either a post-RP prostate-specific antigen (PSA) nadir > 0.2 ng/mL and a Gleason score ≥7 or a PSA nadir ≤0.2 ng/mL, a Gleason score ≥8, and a pathologic tumor (pT) classification ≥ pT3 received 6 months of androgen-deprivation therapy (ADT) plus radiotherapy and 6 cycles of docetaxel...
July 1, 2017: Cancer
https://www.readbyqxmd.com/read/28289065/gleason-grade-grouping-of-prostate-cancer-is-of-prognostic-value-in-asian-men
#13
Joe Yeong, Rehena Sultana, Jonathan Teo, Hong Hong Huang, John Yuen, Puay Hoon Tan, Li Yan Khor
AIM: The International Society of Urological Pathology made recommendations for the use of Grade Groups (GG) originally described by Epstein and colleagues over Gleason score (GS) alone in 2014, which was subsequently adopted by the WHO classification in 2016. The majority of studies validating this revision have been in Caucasian populations. We therefore asked whether the new GG system was retrospectively associated with biochemical disease-free survival in a mixed-ethnicity cohort of Asian men...
March 13, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28063191/salvage-high-intensity-focused-ultrasound-hifu-for-locally-recurrent-prostate-cancer-after-failed-radiation-therapy-multi-institutional-analysis-of-418-patients
#14
MULTICENTER STUDY
Sebastien Crouzet, Andreas Blana, Francois J Murat, Gilles Pasticier, Stephen C W Brown, Giario N Conti, Roman Ganzer, Olivier Chapet, Albert Gelet, Christian G Chaussy, Cary N Robertson, Stefan Thuroff, John F Ward
OBJECTIVE: To report the oncological outcome of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after external beam radiotherapy (EBRT) from a multicentre database. PATIENTS AND METHODS: This retrospective study comprises patients from nine centres with local recurrent disease after EBRT treated with S-HIFU from 1995 to 2009. The biochemical failure-free survival (bFFS) rate was based on the 'Phoenix' definition (PSA nadir + 2 ng/mL)...
June 2017: BJU International
https://www.readbyqxmd.com/read/28040309/delineating-biochemical-failure-with-68-ga-psma-pet-following-definitive-external-beam-radiation-treatment-for-prostate-cancer
#15
George Hruby, Thomas Eade, Andrew Kneebone, Louise Emmett, Lesley Guo, Bao Ho, Ed Hsiao, Geoff Schembri, Julia Hunter, Carol Kwong
BACKGROUND AND PURPOSE: We investigated the role of (68)Ga-PSMA-PET (PSMA) to determine the location of disease recurrence in those with a rising PSA following definitive external beam radiation treatment (EBRT). MATERIALS AND METHODS: 538men were treated with image guided EBRT to a dose of 78 or 82Gy between 2007 and 2014. Patients at least 24months post EBRT with biochemical failure (nadir+2) underwent PSMA scanning. Local recurrence (LR) was defined as increased uptake within the prostate or seminal vesicles...
January 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27863963/the-dose-response-of-salvage-radiotherapy-following-radical-prostatectomy-a-systematic-review-and-meta-analysis
#16
Christopher R King
PURPOSE/OBJECTIVES: To date neither the optimal radiotherapy dose nor the existence of a dose-response has been established for salvage RT (SRT). MATERIALS/METHODS: A systematic review from 1996 to 2015 and meta-analysis was performed to identify the pathologic, clinical and treatment factors associated with relapse-free survival (RFS) after SRT (uniformly defined as a PSA>0.2ng/mL or rising above post-SRT nadir). A sigmoidal dose-response curve was objectively fitted and a non-parametric statistical test used to determine significance...
November 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27663393/prostate-specific-antigen-vs-magnetic-resonance-imaging-parameters-for-assessing-oncological-outcomes-after-high-intensity-focused-ultrasound-focal-therapy-for-localized-prostate-cancer
#17
Louise Dickinson, Hashim U Ahmed, Richard G Hindley, Neil McCartan, Alex Freeman, Clare Allen, Mark Emberton, Alex P Kirkham
INTRODUCTION: Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies. However, there is currently no validated method for monitoring treatment success. We assessed the diagnostic performance of prostate-specific antigen (PSA) parameters and MRI compared to histological outcomes following focal therapy. PATIENTS AND METHODS: Patients from 3 Ethics Review Board approved prospective studies of focal high intensity-focused ultrasound (HIFU) (Sonablate 500) for localized prostate cancer (T1c-T3a, Gleason grade≤4+3, and PSA≤20)...
January 2017: Urologic Oncology
https://www.readbyqxmd.com/read/27431499/psa-nadir-as-a-predictive-factor-for-biochemical-disease-free-survival-and-overall-survival-following-whole-gland-salvage-hifu-following-radiotherapy-failure
#18
T T Shah, M Peters, A Kanthabalan, N McCartan, Y Fatola, J van der Voort van Zyp, M van Vulpen, A Freeman, C M Moore, M Arya, M Emberton, H U Ahmed
BACKGROUND: Treatment options for radio-recurrent prostate cancer are either androgen-deprivation therapy or salvage prostatectomy. Whole-gland high-intensity focussed ultrasound (HIFU) might have a role in this setting. METHODS: An independent HIFU registry collated consecutive cases of HIFU. Between 2005 and 2012, we identified 50 men who underwent whole-gland HIFU following histological confirmation of localised disease following prior external beam radiotherapy (2005-2012)...
September 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27422297/pathological-oncologic-and-functional-outcomes-of-a-prospective-registry-of-salvage-high-intensity-focused-ultrasound-ablation-for-radiorecurrent-prostate-cancer
#19
Khurram M Siddiqui, Michele Billia, Andrew Arifin, Fan Li, Philippe Violette, Joseph L Chin
PURPOSE: In this prospective registry we prospectively assessed the oncologic, functional and safety outcomes of salvage high intensity focused ultrasound for radiorecurrent prostate cancer. MATERIALS AND METHODS: A total of 81 men were prospectively recruited and evaluated at regular scheduled study visits to 6 months after high intensity focused ultrasound and thereafter as per standard of care. Transrectal ultrasound guided biopsy was performed at 6 months. The primary end point was absence or histological persistence of disease at 6-month biopsy...
January 2017: Journal of Urology
https://www.readbyqxmd.com/read/27376359/-focal-dose-escalation-in-the-treatment-of-prostate-cancer-long-term-results-of-hdr-brachytherapy
#20
J Cordes, J Broschk, M Sommerauer, D Jocham, A S Merseburger, C Melchert, G Kovács
BACKGROUND: We prospectively examined the effect and the safety of intensity-modulated HDR brachytherapy (IMBT) with focal dose escalation. MATERIALS AND METHODS: A total of 139 patients undergoing primary therapy for prostate cancer and 11 patients with recurrence were included. Data analysis focused on the following factors: date of primary diagnosis, Gleason score, initial prostate-specific antigen (PSA) value, PSA nadir, volume of the prostate in the transrectal ultrasound, biopsy of the prostate gland, androgen deprivation, chemotherapy, uroflowmetry, pre- and postoperative post-void residual urine (PVR), number of the needles in the prostate lobes and analysis of follow-up data...
February 2017: Der Urologe. Ausg. A
keyword
keyword
76409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"